PMTA Lawsuit Targets FDA's 180-Day Review Clock

On September 2, 2026, two Altria subsidiaries asked a federal court to throw out the rule that governs how the FDA reviews premarket tobacco product applications. For e-liquid brands and distributors, this is not a fight about one denied product. It is a fight about when the statutory review clock starts running at all, and the answer could reshape the timeline every PMTA-bound company plans around.

Who Filed, and What They Are Asking For

Helix Innovations LLC, which makes on! nicotine pouches, and e-cigarette maker NJOY LLC filed suit alongside the Texas Food & Fuel Association and two Texas retailers, GWT Distributing LLC and Hometown Liquor LLC. The defendants are the FDA, the Department of Health and Human Services, and Acting Commissioner of Food and Drugs Kyle Diamantas. The case was filed in the U.S. District Court for the Northern District of Texas, Lubbock Division, as Case No. 5:26-cv-00199-H.

The plaintiffs want the court to declare the FDA's 2021 PMTA final rule unlawful and vacate it, order the agency to build a new review process that fits the statutory deadline, and bar enforcement of premarket requirements against certain Helix and NJOY products whose applications have been pending more than 180 days. Reuters reported that an FDA official said the agency is committed to facilitating access to less harmful alternatives for adult smokers while protecting young people, and that it would carefully review the issues raised.

The 180-Day Question at the Center of the Case

Under 21 U.S.C. 387j, the FDA must act on a premarket tobacco product application as promptly as possible and in no event later than 180 days after receipt of an application. The dispute is about what counts as receipt of an application.

The FDA's 2021 rule, published at 86 Fed. Reg. 55,300 on October 5, 2021, formalizes staged review. Under 21 CFR 1114.27, the agency runs an Acceptance Review, then a Filing Review to decide whether a submission holds enough information for substantive scientific evaluation, and the regulation frames the 180 days as running from receipt of an application that meets filing requirements. The plaintiffs argue those gates improperly push back the start of the statutory clock, and that the rule loads applicants with information demands the agency never adequately justified, particularly for non-combustible products.

Those are allegations. No court has ruled that the FDA's reading of the 180-day requirement or the 2021 rule is unlawful, and the case is at the complaint stage.

The Delay Record the Complaint Leans On

The complaint cites the plaintiffs' own filings. Helix submitted 45 PMTAs for its original on! pouch products on May 15, 2020; the complaint states those applications had been pending more than 2,270 days when the suit was filed. NJOY submitted supplemental PMTAs for its ACE device and pods in November 2025 and says final orders had not issued within 180 days under its reading of the statute.

Independent of the plaintiffs, a 2023 HHS Office of Inspector General audit examined the FDA's review of electronic nicotine delivery system applications and found that for all 15 authorized ENDS products in its sample, the agency did not issue marketing orders within the 180-day timeline. As of October 2022, the audit also found the FDA had not decided applications covering 53,128 of the roughly 6.7 million ENDS products submitted by the September 2020 deadline. The same audit found the agency generally followed applicable statutes, regulations, and procedures in the decisions it did review.

The FDA Says the Backlog Is Already Shrinking

The agency's position is that it is fixing the pace without replacing the rule. In a May 7, 2026 statement, CTP Acting Director Bret Koplow wrote that the center reduced its application backlog by roughly 70 percent during 2025 and that, for the first time in years, there is no longer a queue for applications pending Acceptance Review. Koplow also described new efficiencies in Filing Review, splitting submissions so products ready for a marketing granted order are not held behind ones still needing information, and a forthcoming pilot for expedited review of certain supplemental PMTAs.

Authorizations have followed. The FDA authorized four Helix nicotine pouches on August 4, eleven ZYN ULTRA pouches on August 21, and the JUUL2 device with tobacco- and menthol-flavored pods on August 28, bringing the authorized e-cigarette list to 48 products alongside 43 authorized nicotine pouches. The plaintiffs' answer is that faster review does not settle the legal question of how the 180 days is counted.

Why B2B Buyers Should Track This One

Whatever the merits, the practical stakes for brands and distributors are about planning. A narrow ruling could resolve relief specific to these plaintiffs and leave the national framework intact. A broader ruling accepting the challenge to the 2021 rule could force the FDA to revisit how the 180-day period is calculated and how Acceptance and Filing Reviews operate, which would change launch timelines, inventory commitments, and capital planning across the category. A final judgment, and certain injunctive rulings, could be appealed to the Fifth Circuit.

It is also worth noting what the filing does not do. It does not invalidate the 2021 rule, suspend premarket requirements, or authorize any product still under review. Federal agencies sued in their official capacities generally have 60 days after service to respond, so nothing about compliance obligations changes in the near term. Anyone planning around a court-driven shift should treat the outcome as genuinely open.

What This Means for Production Discipline

Cases like this reward companies whose documentation is already in order. The information burden the plaintiffs are contesting, formulation detail, manufacturing controls, and batch-level records, is the same material that determines how quickly a company can respond when the agency comes back with questions in real-time communication. Whether the clock starts at receipt or after Filing Review, the applicant who can produce a clean, consistent record moves faster.

Nova Manufacturing is a US e-liquid contract manufacturer built around that discipline: standardized formulations that hold across production runs, batch documentation that traces every ingredient and lot, and GMP-quality production practices designed to withstand scrutiny. If you are weighing what a shifting PMTA timeline means for your product roadmap, or you need a manufacturing partner whose records will stand up to a regulatory file review, get in touch with our team.